Rare disorder potentially indicated for transplant or complication after transplantation

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:565779
Who is this for?
Show terms as
2FDA treatments2Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet code 565779 refers to a rare disorder that is either a condition for which organ or stem cell transplantation may be considered as a treatment, or a complication that arises after a transplant has been performed. This broad category covers a wide range of serious conditions where the body's organs or immune system are severely affected — sometimes to the point where replacing a failing organ (such as the liver, kidney, heart, or bone marrow) becomes necessary to save a person's life. After a transplant, the body can face new challenges. The immune system may attack the new organ (a process called rejection), or the new immune cells from a donor may attack the recipient's body (known as graft-versus-host disease, or GVHD). Infections, organ dysfunction, and medication side effects are also common concerns in the post-transplant period. Because this Orphanet code covers a group of conditions rather than a single disease, symptoms, treatments, and outcomes vary widely depending on the specific underlying disorder. Management typically involves a specialized transplant team, immunosuppressive medications to prevent rejection, and close long-term monitoring. Early identification of complications is critical to improving outcomes for patients in this category.

Key symptoms:

Organ failure or severely reduced organ functionExtreme fatigue and weaknessFrequent or severe infectionsSkin rash or blistering (possible sign of graft-versus-host disease)Jaundice (yellowing of the skin or eyes)Nausea, vomiting, or diarrheaSwelling in the legs or abdomenShortness of breathFever without a clear causeUnexplained weight lossBleeding or bruising easilyConfusion or changes in mental alertness

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

6 events
Jun 2025Autologous Serum Obtained by a Closed-Circuit Collection Device

GIANCARLO FATOBENE — PHASE2

TrialNOT YET RECRUITING
Oct 2023MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib

Sichuan University — PHASE2

TrialNOT YET RECRUITING
Dec 2021PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Henry Ford Health System — PHASE1

TrialRECRUITING
Nov 2018Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Hospital Israelita Albert Einstein — PHASE2, PHASE3

TrialRECRUITING
Feb 1999

Busulfex: FDA approved

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.

FDAcompleted
Apr 1986

Digibind: FDA approved

Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

2 available

Busulfex

Busulfan· Otsuka Pharmaceutical Company, Ltd■ Boxed WarningOrphan Drug

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.

Digibind

Digoxin immune FAB (Ovine)· Glaxo Wellcome Inc.Orphan Drug

Clinical Trials

2 recruitingView all trials with filters →
Phase 11 trial
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Phase 1
Actively Recruiting
· Sites: Detroit, Michigan · Age: 1870 yrs

No specialists are currently listed for Rare disorder potentially indicated for transplant or complication after transplantation.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Rare disorder potentially indicated for transplant or complication after transplantation.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Rare disorder potentially indicated for transplant or complication after transplantationForum →

No community posts yet. Be the first to share your experience with Rare disorder potentially indicated for transplant or complication after transplantation.

Start the conversation →

Latest news about Rare disorder potentially indicated for transplant or complication after transplantation

No recent news articles for Rare disorder potentially indicated for transplant or complication after transplantation.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific condition do I have, and why is transplant being considered for me?,What type of transplant would I need, and how do I get on the waiting list?,What are the most likely complications I should watch for after transplant?,What medications will I need to take long-term, and what are their side effects?,How will this condition and the transplant affect my daily life, work, or school?,Are there clinical trials or newer treatments I should know about?,What support services or patient organizations are available to help me and my family?

Common questions about Rare disorder potentially indicated for transplant or complication after transplantation

What is Rare disorder potentially indicated for transplant or complication after transplantation?

Orphanet code 565779 refers to a rare disorder that is either a condition for which organ or stem cell transplantation may be considered as a treatment, or a complication that arises after a transplant has been performed. This broad category covers a wide range of serious conditions where the body's organs or immune system are severely affected — sometimes to the point where replacing a failing organ (such as the liver, kidney, heart, or bone marrow) becomes necessary to save a person's life. After a transplant, the body can face new challenges. The immune system may attack the new organ (a p

Are there clinical trials for Rare disorder potentially indicated for transplant or complication after transplantation?

Yes — 2 recruiting clinical trials are currently listed for Rare disorder potentially indicated for transplant or complication after transplantation on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

What treatment and support options exist for Rare disorder potentially indicated for transplant or complication after transplantation?

2 patient support programs are currently tracked on UniteRare for Rare disorder potentially indicated for transplant or complication after transplantation. See the treatments and support programs sections for copay assistance, eligibility, and contact details.